AbbVie Joins Avaxia Board, Becomes An Early Investor In The Gut Therapy Biotech
This article was originally published in The Pink Sheet Daily
AbbVie has been filling out its pipeline with small deals that could result in a follow-on drug to its blockbuster Humira; it’s most recent investment is in a small company doing further work in the space.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.